Assessment and Management of Hyperkalemia in the Hospital Setting: Optimizing Patient Outcomes

 

 

PROGRAM OVERVIEW

The risk of hyperkalemia increases significantly for patients with chronic kidney disease (CKD) and for those who take common medications for heart failure (HF), such as RAAS inhibitors, which can increase potassium in the blood. Hyperkalemia occurs in 23% to 47% of patients with CKD and/or HF, with an estimated 200 million and 38 million people, respectively, living with each condition worldwide. If not treated rapidly, severe hyperkalemia may lead to cardiac arrest and death.

Healthcare providers involved in the care of patients with hyperkalemia would benefit from education on current epidemiologic and clinical trial data surrounding acute and chronic hyperkalemia, in order to develop management strategies that address this electrolyte abnormality in ways that provide the most optimal outcome for affected individuals. This includes identifying those at risk for developing hyperkalemia as well as employing evidenced-based therapies that have been shown to improve outcomes in persons with CKD, HF, hypertension (HTN), and/or diabetes mellitus (DM). Benefits of multidisciplinary transitional strategies will also be discussed in this activity.

FACULTY

Bruce S. Spinowitz, MD
Associate Director, Nephrology
Vice Chairman, Department of Medicine
New York-Presbyterian Queens
Professor of Clinical Medicine
Weill Cornell Medical College
Flushing, New York

 

Release date: July 30, 2020
Expiration date: July 30, 2021
Estimated time to complete activity: 1.0 hour

 

TARGET AUDIENCE

This educational initiative has been designed for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists who practice in hospital and internal medicine settings.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Identify factors that increase risk for hyperkalemia
  • Discuss the relationship between RAAS inhibitors and hyperkalemia development in patients with CKD, HF, HTN, and/or DM
  • Apply to practice an understanding of clinical trial evidence for the efficacy and safety of newer potassium binders approved for treating hyperkalemia
  • Employ a multidisciplinary, team-based approach to improve outcomes for patients with hyperkalemia
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity. During the period of July 30, 2020 through July 30, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Pharmacists must check the CPE monitor for their credits within 60 days of the activity.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this free live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

Global Education Group designates this free continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Numbers – 0530-9999-20-075-H01-P.)

This is a knowledge-based activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This free educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or cme@globaleducationgroup.com.

SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLOSURE OF CONFLICTS OF INTEREST (COI)

Integrity Continuing Education and Global Education Group requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity: Lindsay Borvansky, Ashley Cann, Andrea Funk, Donna Fausak, Liddy Knight, Ashley Marostica, RN, MSN, and Michelle R. Rizzo, ELS.

FACULTY DISCLOSURES

Bruce S. Spinowitz, MD
Consulting Fees: Akebia Therapeutics, AstraZeneca, Reata Pharmaceuticals.
Contracted Research: Akebia Therapeutics, AstraZeneca, Bayer, Gilead, GlaxoSmithKline, Reata Pharmaceuticals.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.
This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

 

Continue to Pretest